Microbiome upstart Vedanta teams up with NYU Langone scientist on checkpoint drugs
Academic collaborations have been central to the development of new immuno-oncology drugs. And now the microbiome startup Vedanta Biosciences is following the same scientific trail in advancing a new set of therapies that could one day play a role in the hot checkpoint inhibitor field.
Building on the work of Vedanta scientific cofounder Kenya Honda at Keio University, the biotech will work with a team of investigators headed by Jeffrey S. Weber, M.D., Ph.D., deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center. They’ll focus on bacterial strains that have shown signs of activating immune cells in the gut to amp up the efficacy of checkpoints like Opdivo and Keytruda, which have roiled the oncology drug market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.